Few studies have examined the cost-effectiveness of the National Diabetes Prevention Program (NDPP) in real-world settings. We evaluated the real-world cost-effectiveness of the NDPP in people with prediabetes in a large workforce with employer-sponsored health insurance. We performed individual-level, empirical data analyses using surveys and health insurance claims for 6,179 adult employees, dependents, and retirees with prediabetes who enrolled (n=592) or did not enroll (n=5,587) in the NDPP. We assessed direct medical costs the year before NDPP enrollment/index date (baseline) through 2 years afterward, EQ-5D-5L utility scores at baseline and 2 years afterward, and quality-adjusted life-years (QALYs) over 2 years for NDPP enrollees and non-enrollees. We applied propensity score weighting to adjust for bias due to self-selection for enrollment, multiple imputations to handle missing data, and bootstrap method to produce confidence intervals (CIs). We adopted a health system perspective and discounted costs and QALYs at 3% annually. Costs were expressed in 2020 U.S. dollars. Compared to non-enrollees, the average reduction in direct medical costs per enrollee was $3,979 (95% CI: -$11,962 to $2,019) over 2 years. The cost savings were primarily related to fewer hospitalizations (-$3,016), outpatient visits (-$639), and emergency room visits (-$272) among enrollees. Each enrollee accrued 1.726 QALYs and each non-enrollee accrued 1.702 QALYs over 2 years, representing a gain of 0.024 (95% CI: -0.007 to 0.052) QALY per enrollee. The uncertainty analyses showed a high probability (75%) of cost savings, and an 89% probability of being cost-effective at a willingness-to-pay threshold of $100,000 per QALY gained, for NDPP enrollees versus non-enrollees. In this real-world population with prediabetes, enrollment in the NDPP was likely to provide cost savings and improve quality-adjusted life-expectancy. Further research is warranted to confirm these findings.

Disclosure

S. Kuo: None. W. Ye: None. D. Wang: None. L.N. McEwen: None. C. Villatoro Santos: None. W.H. Herman: Consultant; Merck Sharp & Dohme Corp. Advisory Panel; American Diabetes Association. Other Relationship; National Institutes of Health. Advisory Panel; National Committee for Quality Assurance.

Funding

National Institute of Diabetes and Digestive and Kidney Diseases (R01DK109995 and P30DK092926), and Centers for Disease Control and Prevention (U18DP006712)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.